[go: up one dir, main page]

AU2001254813A1 - Regulation of nf-at interacting protein nip 45 variant - Google Patents

Regulation of nf-at interacting protein nip 45 variant

Info

Publication number
AU2001254813A1
AU2001254813A1 AU2001254813A AU5481301A AU2001254813A1 AU 2001254813 A1 AU2001254813 A1 AU 2001254813A1 AU 2001254813 A AU2001254813 A AU 2001254813A AU 5481301 A AU5481301 A AU 5481301A AU 2001254813 A1 AU2001254813 A1 AU 2001254813A1
Authority
AU
Australia
Prior art keywords
nip
interacting protein
variant
regulation
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001254813A
Inventor
Jeffrey Encinas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2001254813A1 publication Critical patent/AU2001254813A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dairy Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed are novel nucleic acid and amino acid sequences of NF-AT interacting protein NIP 45 variants. Reagents that bind to NIP45-variant gene products can be used to treat conditions involving inflammatory processes, such as allergy, asthma, autoimmune diseases, and other chronic inflammatory diseases where an over-activation or prolongation of the activation of the immune system causes damage to tissues.
AU2001254813A 2000-04-25 2001-04-25 Regulation of nf-at interacting protein nip 45 variant Abandoned AU2001254813A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19935600P 2000-04-25 2000-04-25
US60199356 2000-04-25
PCT/EP2001/004635 WO2001081574A2 (en) 2000-04-25 2001-04-25 Regulation of nf-at interacting protein nip 45 variant

Publications (1)

Publication Number Publication Date
AU2001254813A1 true AU2001254813A1 (en) 2001-11-07

Family

ID=22737188

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001254813A Abandoned AU2001254813A1 (en) 2000-04-25 2001-04-25 Regulation of nf-at interacting protein nip 45 variant

Country Status (8)

Country Link
EP (1) EP1280897B1 (en)
JP (1) JP2003530883A (en)
AT (1) ATE340261T1 (en)
AU (1) AU2001254813A1 (en)
DE (1) DE60123235T2 (en)
DK (1) DK1280897T3 (en)
ES (1) ES2272471T3 (en)
WO (1) WO2001081574A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002214005A1 (en) * 2000-10-10 2002-04-22 Bayer Aktiengesellschaft Regulation of nf-at interacting protein nip 45 like protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1225682A (en) * 1996-04-23 1999-08-11 哈佛大学校长及研究员协会 Method and compositions for regulating T cell subsets by modulating transcription facter activity
GB9722388D0 (en) * 1997-10-24 1997-12-24 Zeneca Ltd NIP45 human homolog

Also Published As

Publication number Publication date
DE60123235D1 (en) 2006-11-02
ES2272471T3 (en) 2007-05-01
ATE340261T1 (en) 2006-10-15
WO2001081574A3 (en) 2002-04-18
DE60123235T2 (en) 2007-09-13
EP1280897A2 (en) 2003-02-05
WO2001081574A2 (en) 2001-11-01
DK1280897T3 (en) 2007-01-08
JP2003530883A (en) 2003-10-21
EP1280897B1 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
AU2002365811A1 (en) Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations
MXPA02012743A (en) Il-17 molecules and uses thereof.
WO2000069896A3 (en) Molecular interactions in haematopoietic cells
WO2004043407A3 (en) Methods and products for treating staphylococcal infections
EP1808180A3 (en) Modified GP 100 and uses thereof
WO2002014485A3 (en) Kallikrein gene
WO2001048209A3 (en) Genes identified as required for proliferation of e. coli
WO2000053776A3 (en) Human kallikrein-like genes
WO2002040668A3 (en) Proteins and dna sequences underlying these proteins used for treating inflammations
WO2003040181A3 (en) Genes from the corynebacterium glutamicum coding for regulatory proteins
WO2003046123A3 (en) Mutated gene from corynebacterium glutamicum
WO1998010076A3 (en) Phospholipase d and dna sequences
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
AU2001254813A1 (en) Regulation of nf-at interacting protein nip 45 variant
WO2002031512A3 (en) Molecular interactions in hematopoietic cells
WO2002030972A3 (en) Regulation of nf-at interacting protein nip 45 like protein
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2001085935A3 (en) Endothelial differentiation gene 6-like g protein coupled receptor
WO2003002599A3 (en) Immune-related proteins and the regulation of the same
PT1322753E (en) NEW REDUCTIONS OF 2,5-DICETO-L-GLUCONIC ACID AND METHODS OF USE
WO2001039786A3 (en) New uses of suppressive macrophage activation factors
WO2009083968A8 (en) Novel protein
WO2000069898A3 (en) Molecular interactions in allergy cells
WO2001077348A3 (en) Ketogulonigenium endogenous plasmids
AU2002323612A1 (en) Novel clark protein and nucleic acid molecules and uses therefor